These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21768880)

  • 21. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
    Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
    Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of glycogen synthase kinase-3beta attenuates glucocorticoid-induced bone loss.
    Wang FS; Ko JY; Weng LH; Yeh DW; Ke HJ; Wu SL
    Life Sci; 2009 Nov; 85(19-20):685-92. PubMed ID: 19782693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
    Kassem M
    APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
    Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
    Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling.
    Shaarawy M; El-Mallah SY; Seoudi S; Hassan M; Mohsen IA
    Contraception; 2006 Oct; 74(4):297-302. PubMed ID: 16982229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel quercetin analogue from a medicinal plant promotes peak bone mass achievement and bone healing after injury and exerts an anabolic effect on osteoporotic bone: the role of aryl hydrocarbon receptor as a mediator of osteogenic action.
    Sharan K; Mishra JS; Swarnkar G; Siddiqui JA; Khan K; Kumari R; Rawat P; Maurya R; Sanyal S; Chattopadhyay N
    J Bone Miner Res; 2011 Sep; 26(9):2096-111. PubMed ID: 21638315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tetracyclines inhibit rat osteoclast formation and activity in vitro and affect bone turnover in young rats in vivo.
    Zhou X; Zhang P; Zhang C; An B; Zhu Z
    Calcif Tissue Int; 2010 Feb; 86(2):163-71. PubMed ID: 20033141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.
    Spadaro JA; Damron TA; Horton JA; Margulies BS; Murray GM; Clemente DA; Strauss JA
    J Orthop Res; 2006 May; 24(5):936-44. PubMed ID: 16609966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
    Gasser JA; Green JR; Shen V; Ingold P; Rebmann A; Bhatnagar AS; Evans DB
    Bone; 2006 Oct; 39(4):787-95. PubMed ID: 16844441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
    Lee SE; Min CK; Yahng SA; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Eur J Haematol; 2011 Jan; 86(1):83-6. PubMed ID: 20946110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of bone remodeling: implications for clinical practice.
    Kenny AM; Raisz LG
    J Reprod Med; 2002 Jan; 47(1 Suppl):63-70. PubMed ID: 11829079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
    Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
    Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocrine disruptors and bone metabolism.
    Agas D; Sabbieti MG; Marchetti L
    Arch Toxicol; 2013 Apr; 87(4):735-51. PubMed ID: 23192238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model.
    Friedlaender GE; Tross RB; Doganis AC; Kirkwood JM; Baron R
    J Bone Joint Surg Am; 1984 Apr; 66(4):602-7. PubMed ID: 6707039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of SERMs on the skeleton.
    Tobias JH
    J Endocrinol Invest; 1999 Sep; 22(8):604-8. PubMed ID: 10532247
    [No Abstract]   [Full Text] [Related]  

  • 36. Short-term effects of corticosteroids on trabecular bone remodeling in old ewes.
    Chavassieux P; Buffet A; Vergnaud P; Garnero P; Meunier PJ
    Bone; 1997 May; 20(5):451-5. PubMed ID: 9145242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of smoke carcinogens on bone.
    Yan C; Avadhani NG; Iqbal J
    Curr Osteoporos Rep; 2011 Dec; 9(4):202-9. PubMed ID: 21874290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Bone health in the oncologic patient].
    D'Oronzo S; Tamma A; Simone V; Longo V; Silvestris F
    Recenti Prog Med; 2012 Oct; 103(10):373-83. PubMed ID: 23114401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pros and cons in "palliative-radical" operations in surgical therapy of bone tumors].
    KONFORTI B
    Khirurgiia (Sofiia); 1961; 14():289-90. PubMed ID: 13752943
    [No Abstract]   [Full Text] [Related]  

  • 40. Osteocytes: New Kids on the Block for Cancer in Bone Therapy.
    Anloague A; Delgado-Calle J
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.